» Articles » PMID: 37746665

Arachidonic Acid Metabolism in Health and Disease

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2023 Sep 25
PMID 37746665
Authors
Affiliations
Soon will be listed here.
Abstract

Arachidonic acid (AA), an n-6 essential fatty acid, is a major component of mammalian cells and can be released by phospholipase A2. Accumulating evidence indicates that AA plays essential biochemical roles, as it is the direct precursor of bioactive lipid metabolites of eicosanoids such as prostaglandins, leukotrienes, and epoxyeicosatrienoic acid obtained from three distinct enzymatic metabolic pathways: the cyclooxygenase pathway, lipoxygenase pathway, and cytochrome P450 pathway. AA metabolism is involved not only in cell differentiation, tissue development, and organ function but also in the progression of diseases, such as hepatic fibrosis, neurodegeneration, obesity, diabetes, and cancers. These eicosanoids are generally considered proinflammatory molecules, as they can trigger oxidative stress and stimulate the immune response. Therefore, interventions in AA metabolic pathways are effective ways to manage inflammatory-related diseases in the clinic. Currently, inhibitors targeting enzymes related to AA metabolic pathways are an important area of drug discovery. Moreover, many advances have also been made in clinical studies of AA metabolic inhibitors in combination with chemotherapy and immunotherapy. Herein, we review the discovery of AA and focus on AA metabolism in relation to health and diseases. Furthermore, inhibitors targeting AA metabolism are summarized, and potential clinical applications are discussed.

Citing Articles

Identifying potential biomarkers and molecular mechanisms related to arachidonic acid metabolism in vitiligo.

Li X, Yang L, Zhu L, Sun J, Xu C, Sun L Front Mol Biosci. 2025; 12:1536477.

PMID: 40078960 PMC: 11896865. DOI: 10.3389/fmolb.2025.1536477.


Role of arachidonic acid metabolism in osteosarcoma prognosis by integrating WGCNA and bioinformatics analysis.

Wang Y, Hsu P, Hu H, Lin F, Wei X BMC Cancer. 2025; 25(1):445.

PMID: 40075313 PMC: 11905593. DOI: 10.1186/s12885-024-13278-3.


Prostaglandins: Biological Action, Therapeutic Aspects, and Pathophysiology of Autism Spectrum Disorders.

Yui K, Imataka G, Ichihashi M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996792 PMC: 11854465. DOI: 10.3390/cimb47020071.


Metabolic phenotypes and fatty acid profiles associated with histopathology of primary aldosteronism.

Yang Y, Liu Y, Williams T, Gao M, Yan Y, Bao M Hypertens Res. 2025; .

PMID: 39939827 DOI: 10.1038/s41440-025-02143-w.


Dual COX-2/TNF-α Inhibitors as Promising Anti-inflammatory and Cancer Chemopreventive Agents: A Review.

Tajdari M, Peyrovinasab A, Bayanati M, Ismail Mahboubi Rabbani M, Abdolghaffari A, Zarghi A Iran J Pharm Res. 2025; 23(1):e151312.

PMID: 39830670 PMC: 11742592. DOI: 10.5812/ijpr-151312.


References
1.
Sacerdoti D, Gatta A, McGiff J . Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat. 2003; 72(1-2):51-71. DOI: 10.1016/s1098-8823(03)00077-7. View

2.
Wei J, Chen S, Guo W, Feng B, Yang S, Huang C . Leukotriene D4 induces cellular senescence in osteoblasts. Int Immunopharmacol. 2018; 58:154-159. DOI: 10.1016/j.intimp.2017.12.027. View

3.
Innis S . Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr. 2003; 143(4 Suppl):S1-8. DOI: 10.1067/s0022-3476(03)00396-2. View

4.
Wang H, Xu Y, Wang M, Cheng C, Bian R, Yuan H . Protective effect of naringin against the LPS-induced apoptosis of PC12 cells: Implications for the treatment of neurodegenerative disorders. Int J Mol Med. 2017; 39(4):819-830. PMC: 5360435. DOI: 10.3892/ijmm.2017.2904. View

5.
Mizuno R, Kawada K, Sakai Y . Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. Int J Mol Sci. 2019; 20(24). PMC: 6940958. DOI: 10.3390/ijms20246254. View